Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 trial gives adults with extensive-stage SCLC sacituzumab govitecan every 21 days together with either atezolizumab or durvalumab as maintenance therapy for up to two years or until the treatment stops working. Effectiveness will be measured by changes in tumor size and the appearance of new tumors on scheduled CT scans and brain MRIs. Participants will have CT scans at six weeks for the first six cycles then every 9–12 weeks and brain MRI every 12 weeks, and may provide optional tissue and blood samples for correlative studies. The goal is to extend the duration of disease control after initial platinum‑etoposide plus immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the trial.
* Male or Female aged 18 years or above.
* Participants must have a histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC) and extensive stage at diagnosis or locally advanced disease and unable to receive curative intent radiation.
* Participants must have received at least four cycles of platinum plus etoposide and at least 2-3 cycles of atezolizumab/ Durvalumab.
* No evidence of progression on restaging CT CAP following 4-6 cycles of Chemo/IO from the last dose of the chemotherapy cycle.
* ECOG performance status of 0-2
* Patients must not have active uncontrolled HIV, HBV, and HCV infections. Well-controlled infections on treatment will be allowed to participate in the trial.
* Patients with stable and asymptomatic brain metastasis.
* Adequate organ function - bone marrow, kidney, and liver.

Exclusion Criteria:

* Significant renal impairment requiring dialysis or hepatic impairment with end-stage liver disease.
* Participants with leptomeningeal disease.
* Participants with a recent diagnosis of heart failure and acute coronary disease within 3 months.
* Participants who are unable to receive immunotherapy with chemotherapy for induction will be excluded, or those immunotherapy was discontinued to manage immune-related adverse events
* Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrolment.
* Patients with prior exposure to anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4) within 12 months of the study is not allowed.

Where it's running

• Henry Ford Cancer- Detroit
  Detroit, Michigan, United States Recruiting

Study contacts

• Study coordinator: Bindu Potugari, MD
• Email: bpotuga1@hfhs.org
• Phone: 888-734-5322

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Obrixtamig with atezolizumab, carboplatin, and etoposide for advanced small cell lung cancer

  This trial will test whether adding obrixtamig to atezolizumab plus carboplatin and etoposide helps people with extensive-stage small cell lung cancer live longer.

  Recruiting at 166 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 241 other locations · NCT07472517

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Iadademstat with SBRT and atezolizumab for extensive-stage small cell lung cancer

  This phase 1b test checks if adding iadademstat to stereotactic body radiotherapy (SBRT) and the immunotherapy atezolizumab is safe and helps control disease in adults with residual, recurrent, or progressive extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting Phase 1 Yale University · New Haven, Connecticut · NCT07113691

• Comparing sacituzumab govitecan to standard care for advanced small cell lung cancer

  This study is testing whether a new treatment called sacituzumab govitecan can help people with advanced small cell lung cancer live longer and feel better compared to standard care.

  Recruiting at 206 sites Phase 3 Gilead Sciences · Anchorage, Alaska and 218 other locations · NCT06801834

• Combining atezolizumab with chemotherapy for relapsed extensive-stage small cell lung cancer

  This study is testing if adding an immunotherapy drug called atezolizumab to standard chemotherapy can help people with relapsed extensive-stage small cell lung cancer live longer and feel better.

  Recruiting at 2 sites Phase 2 Gruppo Oncologico Italiano di Ricerca Clinica · Aviano (PN) and 24 other locations · NCT06663098

• Combining iadademstat with immunotherapy for advanced small cell lung cancer

  This study is testing whether adding a new drug called iadademstat to standard immunotherapy can help people with advanced small cell lung cancer live longer without their disease getting worse.

  Recruiting at 33 sites Phase 1/2 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06287775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.